Australian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed the first stage of the Remplir US 510(k) market authorisation nerve repair study. …
Orthocell completes all nerve repair surgeries in Remplir US market authorisation study
March 25, 2024 Australian Biotech
Latest Video
New Stories
-
'Patient-centric partnerships will unlock brighter and more equitable outcomes for all'
October 21, 2025 - - Latest News -
Vaccine confidence slips as Australians grow more concerned about access to healthcare
October 20, 2025 - - Latest News -
NZ's Pharmac proposes new rules to manage 'Options for Investment' list - make it shorter
October 20, 2025 - - Latest News -
Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies
October 20, 2025 - - Australian Biotech -
Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum
October 20, 2025 - - Australian Biotech -
Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome
October 20, 2025 - - Australian Biotech -
Biogen earns fourth 'Great Place to Work' certification, strengthening culture of inclusion
October 20, 2025 - - Latest News